FATE - Fate Therapeutics Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript
Fate Therapeutics, Inc. (FATE) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Edward Dulac - Chief Financial Officer Dan Shoemaker - Chief Scientific Officer Bob Valamehr - Chief Development Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Matt Biegler - Oppenheimer Kelsey Goodwin - Guggenheim Securities Ben Burnett - Stifel Biren Amin - Jefferies Daina Graybosch - SVB Leerink Biren Amin - Jefferies Mara Goldstein - Mizuho Securities Alethia Young - Cantor Fitzgerald Presentation Operator Welcome to the Fate Therapeutics Third Quarter 2020 Financial Results Conference Call. At this time, all participants are in listen-only mode. This call is being webcast live on the Investors and Media section of Fate's website at fatetherapeutics.com. As a reminder, today's call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of
For further details see:
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript